Zobrazeno 1 - 10
of 1 260
pro vyhledávání: '"Kazuhiko, Nakagawa"'
Autor:
Satoshi Ikeda, Kazuo Hasegawa, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Shinsuke Hamasaki, Sachiko Watanabe, Aki Yoshikawa, Takayuki Takahama, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
ABSTRACT Background Previous reports indicated still low implementation rates of multigene testing for advanced non‐small cell lung cancer (NSCLC) in Japan. Methods This is a retrospective study launched at the initiative of lung cancer patients. P
Externí odkaz:
https://doaj.org/article/e197cdaf76fd4e8d825004f842e54426
Autor:
Hirotsugu Kenmotsu, MD, PhD, Kazuko Sakai, PhD, Keita Mori, PhD, Terufumi Kato, MD, Shunichi Sugawara, MD, PhD, Keisuke Kirita, MD, PhD, Yasuto Yoneshima, MD, PhD, Koichi Azuma, MD, PhD, Kazumi Nishino, MD, PhD, Shunsuke Teraoka, MD, Ryo Koyama, MD, PhD, Ken Masuda, MD, PhD, Hidetoshi Hayashi, MD, PhD, Ryo Toyozawa, MD, PhD, Satoru Miura, MD, PhD, Yuki Sato, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuto Nishio, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100716- (2024)
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive EGFR mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus beva
Externí odkaz:
https://doaj.org/article/4c7148e01a2e473a80756678fc890a30
Autor:
Atsushi Miyamoto, Hirofumi Michimae, Yasuharu Nakahara, Shinobu Akagawa, Kazuhiko Nakagawa, Yuji Minegishi, Takashi Ogura, Shigeto Hontsu, Hiroshi Date, Kazuhisa Takahashi, Sakae Homma, Kazuma Kishi, Investigators Group for Lung Cancer and IIP
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Effective treatment for advanced lung cancer and idiopathic interstitial pneumonia (IIP) remains an unmet medical need. The relationship between chemotherapy’s effectiveness in advanced lung cancer and the risk of acute exacerbation of IIP
Externí odkaz:
https://doaj.org/article/e324891d132b401ca7a0d805bde41bac
Autor:
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen‐Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 305-316 (2024)
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC). Although the primary endpo
Externí odkaz:
https://doaj.org/article/5ef9670861fa45fda1c2e13f031a8170
Autor:
Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, Koji Haratani, Daisuke Hayakawa, Masahide Oki, Shinnosuke Takemoto, Tomohiro Ozaki, Yusaku Akashi, Akito Hata, Hiroya Hashimoto, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21097-21110 (2023)
Abstract Background Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non‐small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGF
Externí odkaz:
https://doaj.org/article/653a72701e5d487b855668fed38c1519
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Autor:
Takeshi Masuda, Satoru Miura, Yuki Sato, Motoko Tachihara, Akihiro Bessho, Atsushi Nakamura, Taichi Miyawaki, Kohei Yoshimine, Masahide Mori, Hideaki Shiraishi, Kosuke Hamai, Koji Haratani, Sumiko Maeda, Eriko Tabata, Chiyoe Kitagawa, Junko Tanizaki, Takumi Imai, Shohei Nogami, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Noboru Hattori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Small amounts of epidermal growth factor receptor (EGFR) T790M mutation (micro-T790M), which is detected using droplet digital PCR (ddPCR) but not conventional PCR, in formalin-fixed and paraffin-embedded (FFPE) samples have been investigate
Externí odkaz:
https://doaj.org/article/e8bde43f8c7f40679382597541262079
Autor:
Kazushige Wakuda, Hirotsugu Kenmotsu, Yuki Sato, Atsushi Nakamura, Hiroaki Akamatsu, Motoko Tachihara, Satoru Miura, Toshihide Yokoyama, Keita Mori, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background The ALTA-1L study compared brigatinib with crizotinib in untreated ALK-rearranged non-small cell lung cancer (NSCLC) patients, demonstrating the efficacy of brigatinib. Although the median progression-free survival (PFS) of brigat
Externí odkaz:
https://doaj.org/article/d9026cc985de4542a52c71143cb58729
Autor:
Hye Ryun Kim, Shunichi Sugawara, Jong‐Seok Lee, Jin‐Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17061-17067 (2023)
Abstract Background ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐lin
Externí odkaz:
https://doaj.org/article/b0fcd685eeec41798eee2fd83380a4ba
Autor:
Chihiro Sato, Hisato Kawakami, Ryo Tanaka, Hironaga Satake, Kentaro Inoue, Yutaka Kimura, Junya Fujita, Ryohei Kawabata, Yasutaka Chiba, Taroh Satoh, Kazuhiko Nakagawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Adjuvant S-1 monotherapy is the standard of care for stage II gastric cancer (GC) after curative resection in Japan, but its efficacy for microsatellite instability–high (MSI-H) tumors has remained unknown. Among a multi-institutional coho
Externí odkaz:
https://doaj.org/article/530edf29753342e095c74eb7211e943c